metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
versus docetaxel
	avelumab alone
	JAVELIN Lung 200 (all population), 2018 Lancet Oncol. 2018; 19:1468-1479 J Thorac Oncol 2021 Apr 9;S1556-0864(21)01832-3. NCT02395172	RCT	mNSCLC - L2 - all population	avelumab	docetaxel	patients with stage IIIB, IV, or recurrent NSCLC with disease progression after previous platinum doublet treatment	396 / 396	some concern	inconclusive	no statistically significant result
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus docetaxel
	avelumab alone
	JAVELIN Lung 200 (PDL1 >1%), 2018 Lancet Oncol. 2018; 19:1468-1479 J Thorac Oncol 2021 Apr 9;S1556-0864(21)01832-3. NCT02395172	RCT	mNSCLC - L2 - PDL1 positive	avelumab	docetaxel	patients with stage IIIB, IV, or recurrent NSCLC with disease progression after previous platinum doublet treatment PDL1 positive population	264 / 265	some concern	suggested	inconclusive 10 % decrease in deaths (OS) (PE)